Glycopyrrolate Injection, Solution
NDC Package 71872-7175-1

11-digit billing NDC: 71872717501
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Glycopyrrolate injection is in AnesthesiaGlycopyrrolate Injection, USP is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. This formulation utilizes a injection, solution delivery system. Marketed by Medical Purchasing Solutions, Llc, this product is identified by NDC 71872-7175 and is authorized under FDA application ANDA210842.

Identification & Billing

NDC Package Code
71872-7175-1
Package Description
1 VIAL, GLASS in 1 BAG / 20 mL in 1 VIAL, GLASS
Product Code
71872-7175
11-Digit Billing Format
71872717501
RxNorm Crosswalk
RxCUI: 238212 - glycopyrrolate 0.2 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Glycopyrrolate
Non-Proprietary Name
Glycopyrrolate
Substance Name
Glycopyrrolate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
GLYCOPYRROLATE .2 mg/mL
Pharmacologic Class
Usage Information
In AnesthesiaGlycopyrrolate Injection, USP is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection, USP may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants.In Peptic UlcerFor use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.

Regulatory & Marketing

Labeler Name
Medical Purchasing Solutions, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA210842
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-11-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71872-7175-1 identifies a specific commercial package of 1 vial, glass in 1 bag / 20 ml in 1 vial, glass of Glycopyrrolate, a human prescription drug labeled by Medical Purchasing Solutions, Llc. This injection, solution is formulated for intramuscular; intravenous use and contains glycopyrrolate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Medical Purchasing Solutions, Llc on July 11, 2019. The current certification is valid through December 31, 2026.

How is this Medical Purchasing Solutions, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71872717501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
71872-7175-1
11-Digit CMS (5-4-2)
71872-7175-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.